Abstract
Kawasaki disease (KD) is acute vasculitis with an unidentified cause. The prevalence of Kawasaki disease is greater in developed countries or regions, also known as developed areas. Throughout 2021, two cases of complete Kawasaki were identified at Perkebunan Jember Klinik Hospital. Using a Harada score of 3, intravenous immunoglobulin (IGIV) treatment screening was calculated. In general, IGIV is used to reduce the risk of abnormalities/damage to the coronary arteries. The purpose of this study is to identify the diagnostic criteria and indications for administering IGIV to children with Kawasaki disease. Qualitative Method with the case report approach. Patients diagnosed with Kawasaki disease must receive therapy and care based on their symptoms and conditions. Kawasaki disease can be treated with a number of different drugs. IGIV can be delivered to Kawasaki disease patients as a form of treatment. IGIV treatment based on Harada Score. Kawasaki disease is a condition that is rarely recognized by the general public. The resulting conclusions are as follows Complete Kawasaki disease is diagnosed by five days of persistent fever plus 4 of the 5 classic symptoms. Screening with a scoring system is needed in making decisions about giving IGIV.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.